Furthermore, developing molecular targeted therapies against dysregulated FOXA1 expression in EMPD is tempting, as the mutations are much more frequent than in breast cancers and the therapy may translate to a breast cancer therapy. This evidence concerns the gene FOXA1 and breast carcinoma.